Drug Search Results
More Filters [+]

Dalazatide

Alternative Names: dalazatide
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Potassium Channel Blocker

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kineta
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dalazatide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers|Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02435342

P1

Completed

Psoriasis

2015-03-01

NCT02446340

P1

Completed

Healthy Volunteers

2014-04-01

Recent News Events